Docs comfy with ePromotion, and many prefer it, says study

Share this article:
Sixty-seven percent of physicians had a positive attitude toward electronic promotional activities, up from 62% a year ago, according to an SDI study.

Additionally, 73% of the physicians surveyed for SDI's ePromotion Annual Study 2008 said pharma's electronic promotional activities (or ePromotion) were equal or superior to traditional face-to-face encounters.

“Through ePromotion, physicians have more time to review product information and review disease state information at their own convenience – at night time or on the weekends,” said Heather Alba, senior manager, promotional audits at SDI.

Other findings from the report include:
  • Sixty-nine percent of the physicians surveyed participated in ePromotional activities in the evening, outside of office hours. 
  • In 2008, the average amount of time spent by a physician on a single ePromotion activity was 18 minutes. 
  • Physicians ranked Merck as the leader in terms of the best ePromotion activities, followed by Pfizer and AstraZeneca respectively. 
The study, which included feedback from approximately 1,000 physicians across 14 specialties, defined ePromotion in three categories: virtual details (promotions without live communication); video details (live online promotion or telephone-assisted internet browsing); and virtual events (seminars, CME and KOL events, web conferences and group discussions).
Share this article:
close

Next Article in News

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.